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Very recently, we demonstrated that the replacement of the human immunodeficiency virus type-1 (HIV-1) gp41 transmem-
brane protein by an Epstein–Barr virus gp220/350-derived membrane anchor resulted in the incorporation of chimeric
envelope (Env) oligomers into Pr55gag virus-like particles (VLPs), exceeding that of wild-type gp160 by a factor of 10. In this
study, we examined the immunostimulatory properties of Pr55gag VLPs to both (i) chimeric HIV-1 gp120 external envelope
proteins and (ii) full-length gp160 presented on the outer surface of the particles. Immunization studies carried out with
VLPs presenting different derivatives of the chimeric and wild-type Env proteins elicited a consistent anti-Pr55gag as well
as anti-Env antibody response in complete absence of additional adjuvants. In both cases, the immune sera exhibited an
in vitro neutralizing activity against homologous HIV-1 infection in MT4 cells. Noteworthy, these VLPs were also capable
of inducing a strong CD8/ cytotoxic T-cell (CTL) response in immunized BALB/c mice that was directed toward a known
CTL epitope in the third variable domain V3 of the gp120 external glycoprotein. However, the induction of V3-loop-specific
CTLs critically depended on the amounts of Env proteins that were presented by the Pr55gag VLPs. Moreover, the CD8/
CTL response was not significantly altered by adsorbing the VLPs to alum or by repeated booster immunizations. These
results illustrate that Pr55gag VLPs provide a safe and effective means of enhancing neutralizing humoral responses to
particle-entrapped gp120 proteins and are also capable of delivering these proteins to the MHC class I antigen processing
and presentation pathway. Therefore, antigenically expanded Pr55gag VLPs represent an attractive approach in the design
of vaccines for which specific stimulation of neutralizing antibodies and cytotoxic effector functions to complex glycoproteins
is desired. q 1997 Academic Press
INTRODUCTION Girard et al., 1991; Mannhalter et al., 1995). However,
large-scale phase III field trials suggested only a lim-
The type of immune response which leads to protec-
ited—if any— effectiveness of recombinant gp120 sub-
tion from an infection might be used as a guiding princi-
unit vaccines in humans (Macilwain, 1994). Potential dis-
ple for the development of an efficient vaccine. In human
advantages of this approach are the low complexity ofimmunodeficiency virus (HIV)-infected individuals, both
these vaccine preparations and their inability to inducehumoral and cell-mediated immune responses are
a strong cytolytic T-cell response.known to be induced, but the potential capacity of either
The cell-mediated immunity has been demonstratedcomponent in preventing an HIV infection is poorly under-
to play an essential role in limiting the severity and dura-stood so far. Neutralizing antibodies appear to be an
tion of a series of viral infections (Byrne and Oldstone,important component of a protective immune response,
1986; Quinnan et al., 1982; Sethi et al., 1983) and thereparticularly in order to clear the virus or at least to reduce
is cumulative evidence to suggest that this may also bethe viral load from the circulation (Ariyoshi et al., 1992;
the case in HIV-infected individuals (Ariyoshi et al., 1995;Clementi et al., 1993). Virtually all neutralizing activity in
Borrow et al., 1994; Plata et al., 1987; Walker et al., 1987).sera of HIV-1-infected humans is directed against the
Gag-, Pol-, Env-, and Nef-specific cytolytic T-cells haveEnv proteins gp120 and gp41 (Weiss et al., 1985, 1986;
been demonstrated early in the course of an HIV-1 infec-Langlade Demoyen et al., 1994). Neutralizing antibodies
tion, prior to the appearence of humoral response, andthat were elicited after immunization of chimpanzees
are presumed to control the initial viremia (Koup and Ho,with HIV Env proteins protected these animals against
1994; Koup et al., 1994; Safrit et al., 1994). Studies onan HIV infection (Berman et al., 1990; Fultz et al., 1992;
long-term nonprogressors (Cao et al., 1995; Huang et al.,
1995), people at high risk (Langlade Demoyen et al.,
1 To whom correspondence and reprint requests should be ad- 1994; Rowland-Jones et al., 1995), uninfected children
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al., 1995) indicate that a CD8/ cytotoxic T-lymphocyte capable of inducing a strong CD8/ cytolytic T-cell re-
sponse in addition to neutralizing antibodies toward gly-(CTL) response is closely involved in delaying the onset
of disease in HIV-infected subjects or even in the clear- coproteins that are exposed on the VLP surface. Thus,
these genetically engineered, nonreplicating VLPs repre-ance of an initial HIV infection.
Therefore a promising HIV candidate vaccine should sent a promising candidate for the development of a safe
and effective AIDS vaccine.be capable of inducing both a strong cell-mediated im-
mune response and high titers of neutralizing antibodies.
Priming of cytolytic T-cells in vivo has been described MATERIALS AND METHODS
for recombinant live viruses (Abimiku et al., 1995; Cox et
Viruses and cells
al., 1993) and for proteins associated with detergent-type
adjuvants such as liposomes (Lopes and Chain, 1992; HIV-1LAI was propagated and titrated on MT4 cells.
MT4 cells were obtained from the American Type CultureNair et al., 1992; Reddy et al., 1992), ISCOMs (Heeg et al.,
1991), or saponin QS-21 (Newman et al., 1992). However, Collection (ATCC; Rockville, MD) and maintained in RPMI
1640 medium containing 10% FCS. The H-2d B- lymphomamany of these approaches are, due to striking safety
considerations, impractical for an application in humans. cell line A20 (TIB208) and the H-2d mastocytoma cell line
P815 (TIB64) were also obtained from the ATCC. P815Polyvalent particulate structures, mainly based on the
hepatitis B (HB) virus surface antigen (Michel et al., 1990; and A20 cells were maintained at 377 in RPMI 1640 me-
dium containing 5% FCS.Schirmbeck et al., 1994) and Ty virus-like particles (VLPs)
(Griffiths et al., 1991; Harris et al., 1992), have been
Monoclonal antibodiesrecently shown to elicit antibody, T-helper as well as
cytotoxic T-cell responses. Reports suggesting that Gag- The V3-specific murine monoclonal antibody (NEA
specific cellular immune responses may delay or abro- 9305) recognizing a central motif of the V3-loop region
gate disease progression (Cheingsong Popov et al., (RIQRGPGRAFVTIGKI) was purchased from DuPont Can-
1991; Johnson et al., 1991; Weber et al., 1987) prompted ada, Inc. (Markham, Ontario). The p24(CA)-specific mono-
others and us to develop an autologous, nonreplicating, clonal antibodies (mabs) 13/5 and 16/4/2 have been pre-
and safe antigen delivery system, which is based on the viously mapped to amino acids 133–158 and 307–336
particle-forming capacity of the HIV-1 Pr55gag precursor within the Pr55gag polyprotein (Wagner et al., 1992).
protein. Accordingly, recombinant Pr55gag VLPs have
been used for the delivery of selected foreign epitopes Synthetic peptides and recombinant antigens
(Griffiths et al., 1993; Wagner et al., 1993, 1994a,b) or
An 18-mer V3LAI peptide (SIRIQRGPGRAFVTIGKI) wascomplete polypeptides (Haffar et al., 1991; Osterrieder et
synthesized in a 9050 peptide synthesizer and purified asal., 1995). The presentation of small epitopes derived
described previously (Modrow et al., 1989). Recombinantfrom the HIV Env precursor gp160 by recombinant Pr55gag
CHO cell-derived, purified gp120LAI was a gift of Genen-VLPs resulted in the induction of both humoral and cellu-
tech Inc. (San Franzisco, CA). Recombinant p24(CA) pro-lar immune responses (Griffiths et al., 1993; Wagner et
tein (pCO1) and heat inactivated HIVLAI viruses wereal., 1996). However, such particles elicited a strong anti-
kindly provided by Matthias Niedrig (Behringwerke AG,body response against the Pr55gag polyprotein, while that
Marburg, Germany).directed to the inserted epitopes was weak (Luo et al.,
1992; Wagner et al., 1996). Therefore, the incorporation
Expression, purification, and biochemical
of physiologically more relevant oligomeric HIV Env pro-
characterization of hybrid Pr55gag/Env VLPs
teins may be advantageous for vaccine purposes, since
they contain a variety of T-helper and CTL epitopes in Baculoviruses (Ac-) expressing full-length Pr55gag
(Wagner et al., 1992) and gp160 as well as three differentaddition to conformational epitopes known to be targets
for cross-neutralizing antibodies (Sattentau and Moore, chimeric variants of the external HIV-1 glycoprotein
gp120 were constructed as previously described in detail1995; Fouts et al., 1997). Very recently, we demonstrated
that replacement of the gp41 transmembrane protein by (Wagner et al., 1995; Deml et al., 1997). Briefly, chimeric
glycoproteins consisted of the HIV external Env proteinan Epstein–Barr Virus gp220/350-derived membrane an-
chor resulted in the incorporation of chimeric envelope gp120 which was C-terminally covalently linked to the
amino-terminus of the gp220/350 TM/CR moiety by a 6-(Env) oligomers into Pr55gag VLPs in amounts significantly
exceeding those of wild-type gp160 (Wagner et al., 1995; amino acid (Ser-Gly-Ser-Gly-Ala-Gly) hinge region to
allow independent folding of both domains (gp120-TM).Deml et al., 1997). Herein, we describe the immunostimu-
latory properties of Pr55gag VLPs toward different variants Additional modifications include truncations of the gp120
carboxy-terminus by 5 amino acids (gp120-5TM) and byof the HIV envelope proteins, which are stably anchored
on the surface of VLPs. To our knowledge, this is the 20 amino acids (gp120-20TM) (Fig. 1). Hybrid Pr55gag/Env
VLPs were produced by coinfection of High Five insectfirst report demonstrating that such particulate structures
are—in the absence of adjuvants or replicating vector— cells with the recombinant baculoviruses AcPr55 and
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Acgp120-TM, Acgp120-5TM, Acgp120-20TM, or Acgp160. analyses demonstrated that the Env-TM chimeras as well
as the wild-type Env proteins are incorporated into VLPsPurification of VLPs was achieved by separating the con-
centrated cell culture supernatants on 10–60% sucrose as higher order oligomers (Deml et al., 1997).
gradients as previously described (Wagner et al., 1994a).
Immunization experimentsHybrid Pr55gag VLP banded at the expected density of
1.13 to 1.19 g/cm3, typical for HIV virions. The antigenic The feasibility of inducing an HIV-specific antibody re-
peak fractions were dialyzed against PBS. Using a Bio- sponse was analyzed by immunizing groups of three
Rad protein assay (Bio-Rad Laboratories, Germany) and New Zealand White rabbits intramuscularly with 100-mg
a commercial p24 sandwich assay format (Abbott Labo- doses of recombinant antigens dissolved in 100 ml PBS.
ratories, Abbott Park, IL), yields of VLPs were calculated Following the priming immunization all animals received
to 2 to 3 mg/L cell culture supernatant. Analysis of the two boosts at Weeks 6 and 10 with the same dose of
pooled antigenic peak fractions by SDS–10% PAGE fol- antigen. Induction of cytolytic T-cell responses was dem-
lowed by Coomassie staining detected comparable onstrated in a BALB/c mouse model (Takahashi et al.,
amounts of the unprocessed 55-kDa Gag precursor and 1988). BALB/c mice (H-2d) were bred under specific
demonstrated the VLP preparations to be 85% pure pathogen-free conditions. Twelve- to sixteen-week-old
(Fig. 1B). Immunoblot analysis performed with a murine female BALB/c mice (3 to 5 mice per group) were injected
V3-loop-specific monoclonal antibody was required to with the indicated amounts of chimeric Pr55gag/Env VLPs,
visualize protein species corresponding to the molecular rgp120LAI , or a synthetic 18-mer V3LAI peptide (SIRIQR-
mass calculated for gp160 and the hybrid Env-TM deriva- GPGRAFVTIGKI) in PBS. Adjuvants were only used where
tives in the antigenic peak fractions (Fig. 1C). Five- to mentioned.
tenfold higher yields of the chimeric glycoproteins (Env-
TM; lanes 4–6) were regularly noted in the antigenic Enzyme-Linked Immunosorbent assay
peak fractions when compared to wild-type Env proteins
Rabbits were bled in 2-week intervals before and after(lane 7). The concentration of the Env proteins incorpo-
the first immunization. Antibodies to inactivated HIV-1LAIrated into the VLP preparations was calculated by West-
virions, recombinant p24(CA), rgp120, or an 18-mer linearern blot analysis and comparison with a calibration curve
V3LAI-loop-derived peptide were detected by enzyme-obtained after serial 2-fold dilutions (0.2–3.2 mg; lanes
linked immunosorbent assay (ELISA) as previously de-8–12) of highly purified recombinant (r) gp120 protein
scribed (Wagner et al., 1996). Positive reactions were(Genentech, Inc.). Additionally, a commercial gp120 cap-
visualized with 0.1% hydrogen peroxide in the presenceture ELISA kit (Intracel Corporation, Cambridge, MA) was
of 3*,3-diaminobenzidine tetrahydrochloride and stoppedused to verify the amounts of particle-entrapped Env pro-
after 10 min with 1 M H2SO4 . Absorbance was deter-teins. Incorporation of Env-TM chimeras into the outer
mined at 492 nm and reactions were considered positivesurface of VLPs was further confirmed by coimmunopre-
if they exceeded the mean absorbance of equal dilutionscipitation of Pr55gag and Env using gp120-specific mono-
of preimmune sera by a factor of 3.clonal antibodies (data not shown) and by negative-stain-
ing immunogold electron microscopic analysis (Figs. 1D
HIV-1 neutralization assay
and 1E), which was performed essentially as described
earlier (Osterrieder et al., 1995). A more detailed immuno- Antisera were heat inactivated at 567 for 30 min. Serial
electron microscopic analysis of VLPs presenting wild- twofold dilutions of each serum were prepared in triplicate
type and chimeric gp120-TM proteins has been pre- and incubated with 20 50% tissue culture infectious doses
of HIV-1LAI for 1 hr at 377. The virus–serum mixture wassented previously. Furthermore, chemical crosslinking
FIG. 1. Hybrid Pr55gag/Env virus-like particles used for immunization. (A) Schematic representation of wild-type HIV gp160 and chimeric Env-TM
glycoproteins expressed on the outer surface of Pr55gag VLPs. The Epstein–Barr virus gp220/350-derived type I transmembrane domain (TM) and
cytoplasmatic region (CR), as well as the amino acids (aa) of the flexible hinge region, are indicated. Abbreviations of the different chimeric genes
are given at the right, the numbers of amino acids encoded by the chimeric genes are each indicated on the top of the constructs. The coexpression
of these Env proteins and the particle-forming HIV Pr55gag polyprotein resulted in formation of Pr55gag/Env chimeric VLPs. (B and C) Characterization
of VLP preparations following sucrose density sedimentation. Recombinant Pr55gag VLPs (lane 3), VLPgp120-TM (lane 4), VLPgp120-5TM (lane 5),
VLPgp120-20TM (lane 6), or VLPgp160 (lane 7) antigens were normalized for p24(CA) and fractionated by SDS–PAGE. Sedimented antigens of
uninfected (lane 1) and wild-type baculovirus-infected High Five cells (lane 2) served as controls. Lanes 8–12 represent 3.2, 1.6, 0.8, 0.4, and 0.2
mg recombinant-made gp120, respectively. (B) Proteins were stained with Coomassie brilliant blue. (C) Alternatively, VLP-derived proteins as well
as the serial twofold dilution of rgp120 were transferred onto a nitrocellulose filter and probed with mab NEA 9305 specific for the gp120 Env
protein. Arrows at the right indicate the positions of the wild-type HIV Gag and Env proteins. The positions of the markers are given on the left (in
kilodaltons). (D and E) Sucrose gradient sedimented Pr55gag VLP (D) and VLPgp120-TM (E) preparations were adsorbed to grids and incubated with
anti-gp120-specific antibody. Bound mabs were detected with an anti-mouse IgG–gold conjugate and analyzed by negative-staining electron
microscopy. (D) No specific surface labeling of particles was seen in negative controls. (E) VLP-entrapped immunogold-labeled gp120-TM proteins
are indicated by black arrows.
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then added to 5 1 104 MT4 cells. Following an incubation groups 1 and 2 were immunized by purified rgp120 or
authentic Pr55gag VLPs without adjuvant. Groups 3–6 re-at 377, 5% CO2 in a humid atmosphere for 6 days, cell
ceived different preparations of Pr55gag/Env chimericcultures were examined for virus release by a commercial
VLPs (VLPgp120-TM, VLPgp120-5TM, VLPgp120-20TM,p24 sandwich assay (Abbott). The neutralizing titer was
and VLPgp160), also administered in absence of any ad-calculated as the reciprocal of the serum dilution that re-
juvant. Antibody titers to purified rp24(CA) and rgp120sulted in 90% reduction of the p24(CA) synthesis com-
were determined by ELISA. All groups of rabbits immu-pared to the equivalent dilution of the preimmune serum
nized with VLPs (groups 2–6) had already developedfrom the same animal (Wagner et al., 1996).
substantial levels of p24(CA)-specific antibodies 2 weeks
after the first booster immunization (Fig. 2A). Additionally,CTL assay
high levels of gp120-specific antibodies were determined
Single-cell suspensions were aseptically prepared from sera derived from groups 3 to 6 (Fig. 2B). Reactive
from spleens of immunized mice 7 to 14 days postimmu- antibodies increased severalfold after the second
nization. Cells were suspended in a-MEM tissue culture booster immunization and reached Pr55gag-specific end-
medium (Gibco BRL, Eggenstein, Germany) supple- point titers of 1:16,000 to 1:64,000 (groups 2–6) and Env-
mented with 10 mM N-2-hydroxyethylpiperazine-N*-2- specific titers of 1:16,000 to 1:64,000 (groups 3– 6).
ethanesulfonic acid buffer, 5 1 1005 b-mercaptoethanol, Thus, despite the 5- to 10-fold varying concentrations
antibiotics, and 10% v/v FCS. Five percent (v/v) of a se- of particle-entrapped Env proteins, VLPgp160 and
lected batch of Con A-stimulated rat spleen cell superna- VLPgp120-TM revealed a comparable capacity to induce
tants (Reimann et al., 1988) was further added to the gp120-specific antibodies. By contrast, Env-specific anti-
culture medium as a source of growth factors. Responder body responses raised in rabbits following repeated ad-
cells (3 1 107) were cocultured with 1.5 1 106 syngeneic, ministration of rgp120 were low (group 1). Even after
V3LAI peptide-pulsed P815 cells (irradiated with 20,000 the second booster immunization the maximum titers of
rad) in 10 ml tissue culture medium in upright 25-cm3 gp120-specific serum antibodies reached only 1:128.
tissue culture flasks in a humidified atmosphere with 7% The neutralizing properties of the rabbit antisera col-
CO2 at 377. Cytotoxic effector populations were harvested lected 2 weeks after the second booster immunization
after 6 days of in vitro culture and washed twice. Serial were assessed by measuring p24(CA) synthesis from
dilutions of effector cells were cultured with 2 1 103 HIVLAI-infected MT4 cells. A murine gp120/V3-specific
target cells in 200-ml round-bottom wells. Targets were monoclonal antibody with a described neutralizing ca-
autologous A20 (H-2d) cells (2 1 104/ml) incubated over- pacity of 1:200 against HIV-1LAI (Ho et al., 1987) was moni-
night at 377 with 1008 M 18-mer V3LAI peptide. Non-pep- tored in each experiment as a positive control. Titers
tide-pulsed cells were used as a negative control. Target were expressed as the serum dilution that reduced the
and control A20 cells were labeled with 51Cr (1 hr at 377, release of p24(CA) from infected cells by 90% com-
20 mCi/106 cells) and washed with cell culture medium pared to the corresponding dilution of the preimmune
prior to being added to the round-bottom wells. After a serum. All Pr55gag/Env-immunized rabbits (groups 3–6)
4 hr incubation at 377, 100 ml of supernatant was col- developed neutralizing antibodies. The neutralizing ca-
lected for gamma counting. The percentage specific re- pacity of the antisera correlated with the titers of gp120-
lease was calculated as [(experimental release 0 spon- specific antibodies but not with the antibody titers di-
taneous release)/(total release 0 spontaneous release) rected to the V3 loop within gp120 (Table 1). Rabbit sera
1 100. Total counts were measured after adding 1% Tri- derived from animals of groups 3 and 6 exhibited a sub-
ton X-100 to the labeled target cells. Spontaneously re- stantial neutralizing capacity of 1:32–1:128 against infec-
leased counts were always less than 20% of the total tivity of the homologous virus. A significant decrease in
counts. Data shown are the means of triplicate cultures. neutralization titers was monitored from antisera raised
Standard errors of the means of triplicate data were al- against VLPgp120-5TM and VLPgp120-20TM (groups 4
ways less than 20% of the mean. and 5). Antisera elicited to both Pr55gag VLPs and rgp120
(without adjuvant) did not block HIVLAI infectivity (Table
1). Pr55gag VLPs are thus potent immunogens exhibitingRESULTS
intrinsic adjuvant properties for generating a humoral
Humoral immune responses of rabbits to hybrid immune response with neutralizing activity to complex
Pr55gag/Env VLPs polypeptides (gp120-TM, gp160) that were presented on
the surface of the VLPs.The capability of hybrid Pr55gag/Env VLPs to induce
Hybrid Pr55gag/gp120-TM particles induce a specificPr55gag- and Env-specific antibodies was investigated in
MHC class I-restricted, CD8/ CTL response in BALB/New Zealand White rabbits (Fig. 2). Six groups of three
c miceanimals each received a priming immunization (im) of
recombinant antigen (100 mg/dose) followed by two im A H-2d-restricted CTL epitope has been previously
identified in the V3 loop of the HIV-1 exterior Env proteinboosts at Weeks 6 and 10 with the same dose. Control
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FIG. 2. Humoral immune response induced in rabbits following immunization with purified chimeric VLPs. Six groups of three rabbits each were
immunized with 100 mg rgp120 (group 1), ‘‘naked’’ Pr55gag VLPs (group 2), or various Pr55gag/Env chimeric VLP preparations as indicated (groups 3–
6). At 2-week intervals following the primary immunizations, serum samples were collected and assayed for HIV-1-specific antibodies by ELISA
with (A) purified rp24(CA) or (B) purified rgp120. Endpoint antibody titers of the immune sera are depicted as the reciprocal of the last dilution giving
the threefold optical OD compared to the preimmune sera. The arrows indicate the times of the secondary and tertiary immunizations. The mean
endpoint titers of three rabbits in each group to the indicated antigens are shown.
gp120 (Takahashi et al., 1988). In order to determine the tions were carried out in complete absence of adjuvant.
Unprimed mice and mice immunized with 10 mg ofcapability of hybrid Pr55gag/Env VLPs to induce a V3-
specific CD8/ CTL response, 20 mg of hybrid VLPgp120- HBsAg 22-nm subviral particles were used as negative
controls. Seven days postimmunization spleen cells wereTM was injected into BALB/c mice intraperitoneally (ip),
subcutaneously (sc), or intravenously (iv). All immuniza- obtained, transferred into culture, and restimulated with
TABLE 1
Serum Antibody and Neutralizing Antibody Titers of Rabbits Immunized with Hybrid Pr55gag/Env VLPs
Reciprocal maximum titers of serum antibodiesb
Rabbit groupa Antigen HIV-1LAI P24(CA) gp120 V3 NTc
1 rgp120 64 16 128 16 8
64 16 128 16 8
64 16 64 16 8
2 Pr55gag VLPs 32,000 32,000 16 16 8
64,000 32,000 16 16 8
32,000 32,000 16 16 8
3 VLPgp120-TM 16,000 16,000 32,000 16 128
16,000 16,000 64,000 16 128
32,000 16,000 32,000 16 32
4 VLPgp120-5TM 16,000 16,000 16,000 16 16
8,000 8,000 16,000 32 16
8,000 4,000 4,000 16 8
5 VLPgp120-20TM 64,000 32,000 16,000 128 32
8,000 8,000 16,000 32 16
16,000 16,000 16,000 16 16
6 VLPgp160 16,000 16,000 16,000 16 32
32,000 64,000 64,000 16 128
16,000 32,000 64,000 16 32
a Five groups of three rabbits each were immunized intramuscularly at Weeks 0, 6, and 10 with 100-mg doses of different VLP preparations
without adjuvant. All antigen preparations were diluted in PBS.
b Serum samples obtained 2 weeks after the second boost immunization were serially diluted and tested for HIV-1LAI , p24(CA)-, gp120-, and V3-
specific antibodies. ELISA titers are expressed as the reciprocal of the serum dilution that gave an absorbance value exceeding that obtained with
the corresponding preimmune sera by a factor of 3.
c HIV-1 neutralizing assays were preformed with the homologous HIV-1LAI strain in MT4 cells. Neutralizing antibody titers (NT) were calculated
by comparison with control wells of virus incubated with an adequate dilution of preimmuine sera and are expressed as the reciprocal of the serum
dilution that inhibited p24(CA) synthesis by more than 90%. The commercial V3-specific monoclonal antibody NEA-9305 (DuPont) (Ho et al., 1987)
gave a reciprocal neutralization titer of 128 in this assay.
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TABLE 2 response in vivo, BALB/c mice were immunized ip with
titrated doses of 100–1 mg of VLPgp120-TM and, for com-PR55gag/Env VLPs Efficiently Prime CD8/ CTLs Irrespective of the
parison, with the same doses of VLPgp160. The amountsRoute of Immunization
of VLP-entrapped gp120-TM and gp160 were estimated
% Specific lysisb on the basis of a gp120 calibration curve as described
Route of under Materials and Methods (Fig. 1C). Accordingly, the
Groupa immunization A20/Pep A20
amounts of gp120-TM presented by the titrated doses of
VLPs ranged from 5 mg gp120 presented by 100 mg VLPs1 ip 52 2
2 sc 49 2 down to 0.05 mg gp120 presented by 1 mg of hybrid VLPs
3 iv 40 3 (Table 3). By contrast, particles presenting gp160 were
characterized by a 5- to 10-fold reduced incorporationa BALB/c mice were immunized with 20 mg of VLPgp120-TM antigens
into the VLPs. The amounts of gp160 presented by thewithout adjuvants. Spleen cells obtained from mice 7 days postimmuni-
titrated doses of VLPs ranged from 1 mg gp160 entrappedzation were restimulated in vivo with 18-mer V3-peptide-pulsed H-2d
P815 cells. by 100 mg VLPs down to 0.01 mg gp160 presented by 1
b The cytotoxic response was read out against H-2d A20 cells pulsed mg of hybrid VLPs (Table 3). Clearly, the induction of a
for 1 hr with 1008 M V3-loop-derived, synthetic 18-mer peptide (A20/ V3-specific CTL response correlated with the amount of
peptide). The E:T ratio was 20:1.
presented Env proteins rather than with the total amount
of the administered antigen. In both cases, CTL reactivity
syngeneic, peptide-pulsed, inactivated cells in a 5-day was reproducibly detected after a single low-dose injec-
mixed lymphocyte-tumor cell culture (MLTC). The H-2d tion of particles corresponding to about 0.2 mg of en-
mastocytoma cell line P815 pulsed with the synthetic 18- trapped gp120-TM or full-length gp160. Lower doses of
mer V3 peptide (SIRIQRGPGRAFVTIGKI) was used as hybrid particles presenting less than 50 ng of Env-derived
stimulator cells in the MLTC. Cells harvested from MLTC polypeptides were not sufficient to prime a V3-specific
were tested for specific cytotoxic activity in a standard CTL response. No V3-specific CTL response was elicited
short-term 51Cr-release assay. Cells from mice primed in mice after administration with titrated doses of rgp120,
by a single injection of 20 mg VLPgp120-TM developed not even with an excess of 25 mg of rgp120 per immuniza-
specific CTL reactivity, irrespective of the route of antigen tion (Table 3).
delivery. The in vivo-primed and in vitro-restimulated cells
lysed peptide-pulsed but not unpulsed A20 targets. Iden-
tical results were obtained by using A20 cells, which CTLs are primed by different variants of Pr55gag/Env
were infected by gp120 recombinant vaccinia viruses, as VLPs
targets in the chromium release assay (data not shown).
As demonstrated earlier by others and by us, this con- To analyze the quality of the various Env constructs
firmed that the 18-mer V3 peptides and Env recombinant with respect to the induction of a primary V3-specific CTL
vaccinia viruses were equally effective in promoting the response, the VLP preparations used for the immuniza-
MHC class I-restricted presentation of the antigenic pep- tions were normalized to 1 mg of VLP-entrapped Env
tide (Takahashi et al., 1988; Wagner et al., 1993; Griffiths proteins as described under Materials and Methods (Fig.
et al., 1993). Specific CTL reactivity was not detected in 1C). Accordingly, the total amount of antigens injected
a primary MLTC in which spleen cells from unprimed intraperitoneally into BALB/c mice was 100 mg for hybrid
BALB/c mice were cocultured with peptide-pulsed stimu- VLPgp160 and 20–25 mg for VLPs presenting the chime-
lator cells. In vivo priming of CTLs was thus required to ric gp120 derivatives gp120-TM, gp120-5TM or gp120-
induce the specific cytolytic response. Priming of mice 20TM, respectively (Figs. 3E–3H). For controls, mice ei-
with hybrid Pr55gag/Env VLPs by the ip, sc, or iv route ther were not immunized or were primed with a molar
was equally efficient (Table 2). The CTL response was excess of 2.5 mg of a synthetic 18-mer V3 peptide (SIR-
not enhanced by repeated booster injections. The ef- IQRGPGRAFVTIGKI), 25 mg of purified rgp120, or 100 mg
fector cells expressed the CD3/CD40CD8/ phenotype, of Pr55gag VLPs (Figs. 3A–3D). All antigen preparations
since they were eliminated by treatment with anti-CD8 were administered without any additional adjuvant. All
antibody plus complement, but were not affected by treat- tested Pr55gag/Env VLP preparations elicited comparable
ment with anti-CD4 antibody plus complement (data not levels of class I-restricted, V3-specific CTL reactivity. This
shown). In contrast, no V3-loop-specific cytolytic activity indicated that the amount of particle-entrapped Env pro-
was observed in unprimed mice or in mice primed with teins rather than the total amount of administered VLPs
HBsAg particles. determined the induction of V3-specific CTLs (Figs. 3E–
Low amounts of Env variants presented by VLPs 3H). By contrast, no priming of V3-specific CTLs was
prime V3-specific CTLs in vivo detected even after immunization with a comparable
dose of ‘‘naked’’ Pr55gag VLPs or a high molar surplus ofTo determine the minimum quantities of VLP-associ-
ated Env proteins necessary to prime a V3-specific CTL synthetic V3 peptide or rgp120 (Figs. 3B–3D).
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TABLE 3
Low Doses of Pr55gag VLP-Entrapped gp120-TM but Not Soluble rgp120 Proteins Prime a V3-specific CTL Response in Vivo
Corresponding quantities of % Specific lysisb
Dose of VLPgp120-TM particle-entrapped
Group used for priming a gp120-TM A20/Pep A20
1 100 mg 5 mg 52 2
2 20 mg 1 mg 45 2
3 4 mg 0.2 mg 18 3
4 1 mg 0.05 mg 5 2
% Specific lysisb
Dose of VLPgp160 Corresponding quantities of
Group used for priminga particle-entrapped gp160 A20/Pep A20
5 100 mg 1 mg 50 2
6 20 mg 0.2 mg 16 4
7 4 mg 0.04 mg 4 3
8 1 mg 0.01 mg 5 2
% Specific lysisb
Dose of soluble rgp120
Group used for priminga A20/Pep A20
9 25 mg 7 2
10 5 mg 5 1
11 1 mg 6 3
12 0.2 mg 4 3
13 Nonimmunized 6 5
a Spleen cells of BALB/c mice primed by an ip injection of the dose of Pr55gag/Env VLPs or rgp120 protein indicated. Spleen cells obtained from
mice 14 days postimmunization were restimulated in vitro with 18-mer V3-peptide-pulsed H-2d P815 cells.
b The cytotoxic response was read out against H-2d A20 cells pulsed for 1 hr with 1008 M V3-loop-derived, synthetic 18-mer peptide (A20/peptide).
The E:T ratio was 20:1.
Primary and boosted responses of B-cells and CD8/ hybrid VLPs adsorbed to alum did not down-regulate the
efficiency of priming a CD8/CTL response. These resultsCTLs of BALB/c mice to different antigen formulation
contrast with previous observations, which indicate that
To compare the humoral (B-cell) and cytolytic T-cell
alum or mineral oil significantly reduced the ability of
response to different formulations of hybrid Pr55gag/Env
chimeric VLPs, presenting the V3 epitope as part of a
VLPs, mice were immunized intraperitoneally with 20 mg
chimeric Pr55gag polyprotein, to stimulate V3-specific
of VLPgp120-TM or 2.5 mg rgp120 in form of naked anti-
CTLs in vivo (Griffiths et al., 1993; Wagner et al., 1996).
gen, adsorbed to aluminum hydroxide (alum), or solubi-
The B-cell response of BALB/c mice to VLPgp120-TM
lized in SDS. A boost immunization with the same antigen
VLP formulations measured in terms of specific serum
formulation was given 3 weeks after the priming injec-
antibody levels appeared 1 to 3 weeks after the first
tion. The CTL reactivity to naked VLPgp120-TM was de-
immunization. Compared with the primary and boosted
tectable as early as 6 days after the first immunization,
antibody responses of mice immunized with naked
persisted for many months, and was not enhanced by
VLPgp120-TM, mice primed and boosted with hybrid par-
boost infections (data not shown). Three weeks after the
ticles adsorbed to alum showed significantly enhanced
booster immunizations, mice injected with hybrid
serum antibody levels, occuring even after the initial im-
VLPgp120-TM adsorbed to alum showed a CTL response
munization. The maximum midpoint titers were 8- to 32-
which was comparable to that in animals primed with
fold higher compared to the antibody levels detectable
naked VLPs. For comparison, no V3-loop-specific CTLs
in mice immunized with hybrid VLPs alone. In contrast,
were induced by injecting mice with rgp120 or rgp120
the pretreatment of particles with SDS resulted in a sig-
adsorbed to alum. Notably, vaccination with SDS-dena-
nificant reduction in their ability to stimulate a HIV-spe-
tured hybrid particles or SDS-denatured rgp120 was at
cific serum antibody response (Table 4).
least equally effective in priming class I-restricted CTLs
(Table 4). Hence, CTL priming by the native, particulate
DISCUSSION
VLPgp120-TM and the SDS-solubilized particle compo-
nent gp120-TM showed striking similarity. Surprisingly, Aiming at the development of more complex HIV candi-
date vaccines, we very recently suggested a novel strat-in this system sensitization of the immune system with
AID VY 8668 / 6a3e$$$441 07-30-97 14:51:26 vira AP: VY
34 DEML ET AL.
FIG. 3. Priming of class I-restricted cytotoxic T lymphocytes with different types of Pr55gag/Env chimeric VLPs. BALB/c mice were immunized with
an ip injection of (E–H) indicated Pr55gag/Env VLP preparations each normalized to 1 mg of particle-associated Env proteins. Control mice were (A)
not immunized or injected with (B) 10 mg of an 18-mer V3 peptide, (C) 25 mg rgp120, or (D) 100 mg naked Pr55gag VLPs. Seven days pi spleen cells
were obtained and specifically restimulated in vitro in a 5-day MLTC using syngeneic P815 mastocytoma cells pulsed with the synthetic V3 peptide
as stimulator cells. The cytotoxic response was read against V3-peptide-pulsed (closed rectangles) or untreated (open rectangles) A20 H-2d B-
lymphoma cells as targets in a standard 4-hr 51Cr-release assay. Data shown were mean values of triplicate cultures. The standard errors of the
means of triplicate data were always less than 15% of the mean.
egy to incorporate high quantities of chimeric gp120 could be further increased following a third administra-
tion of hybrid VLPs. Additional boosts did not alter theoligomers at the outer surface of highly immunogenic
Pr55gag virus-like particles (Deml et al., 1997). Due to the antibody titers (data not shown). The presence of high
titers of Env-specific antibodies was especially encour-absence of the authentic gp41 transmembrane protein,
the VLP-associated chimeric gp120 polypeptides might aging since the administered VLP preparations con-
tained only low amounts of Env proteins (approximatelypossess some intrinsic advantages for vaccine pur-
poses: (i) an exclusion of potential immunosuppressive 1–5 mg depending on the type of Pr55gag/Env VLP). More-
over, administration of soluble rgp120 without adjuvanteffects and adverse immune reactions suggested to be
induced by gp41 (Ruegg et al., 1989; Ruegg and Strand, resulted in only a weak Env-specific antibody response,
even following the second booster inoculation. These1991; Yamada et al., 1991), (ii) a 5- to 10-fold increased
incorporation of oligomeric gp120 chimeras on the sur- results are in agreement with previous studies, propos-
ing that viral Env proteins presented in the context offace of immunostimulatory Pr55gag VLPs compared to full-
length gp160, and (iii) the absence of diagnostically rele- particulate carriers or as aggregates enhance the stimu-
lation of a specific immune response (Cabral et al., 1978).vant gp41-associated epitopes, which would allow one to
distinguish vaccinees and HIV-infected people in future Possibly, the polyvalent nature of the antigen facilitates
an efficient uptake by antigen-presenting cells or is im-vaccination studies on a serological basis.
Herein, we describe the immunostimulatory properties portant for the cross-activation of different immune-com-
petent cells.of recombinant Pr55gag VLPs to the HIV-1 external glyco-
protein gp120 presented in large quantities on the outer Interestingly, only low titers of V3-specific antibodies
were induced by immunizing rabbits with Pr55gag VLPssurface of the particles. The magnitude of the antibody
response to different preparations of purified Pr55gag/Env presenting oligomeric Env proteins. This may be ex-
plained by previous reports demonstrating that the bulkVLPs was determined in New Zealand White rabbits. All
groups of animals immunized with different types of of the V3 loop is masked on oligomeric forms of gp120.
Consistent with this observation, immunization withPr55gag/Env particles developed substantial levels of
gp120- in addition to Pr55gag-specific antibodies immedi- oligomeric gp120 resulted in a low frequency of V3-loop
reactivity, suggesting that the V3 loop may not be anately after the second immunization. These responses
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TABLE 4
Antibody and CTL Responses of BALB/c Mice to Different Formulations of Pr55gag/gp120-TM VLPs
Serum antibody titersb % Specific lysisc
VLPgp120-TM
Group antigen formulationa HIV-1 lysate p24(CA) rgp120 A20/Pep A20
1 Naked 512 1,024 1,024 46 1
2 Plus alum 16,000 16,000 8,200 43 6
3 Plus SDSd 128 128 64 55 3
Serum antibody titersb % Specific lysisc
rgp120
Group antigen formulationa HIV-1 lysate p24(CA) rgp120 A20/Pep A20
4 Naked 64 16 64 3 1
5 Plus alum 1,028 16 2,056 5 4
6 Plus SDSd 32 32 32 59 3
7 Nonimmunized 16 16 16 8 3
a BALB/c mice were immunized ip with 20 mg of VLPgp120-TM or 2.5 mg of rgp120 in form of naked antigen preparations (groups 1 and 4),
adsorbed to alum (groups 2 and 5), or denatured in SDS (groups 3 and 6). A control group included unprimed BALBc mice (group 7). Three weeks
after the priming immunization, mice received a boost injection with the same dose of antigen. Specific antibody and CTL levels were determined
from immunized mice 3 weeks after the boost injection. The mean values of three individual mice in each group are shown.
b Serum samples obtained 3 weeks after the boost immunization were serially diluted and tested for HIV-1LAI-, p24(CA)-, and gp120-specific antibodies
by enzyme-linked immunosorbent assay. Titers are expressed as the reciprocal of the serum dilution that gave an absorbance value three times
higher than the value obtained with the corresponding preimmune sera.
c Spleen cells obtained 3 weeks after the boost immunization were restimulated in vitro with 18-mer V3-peptide-pulsed H-2d P815 cells. The
cytotoxic response was read against H-2d A20 cells pulsed for 1 hr with 1008 M V3-loop-derived synthetic 18-mer peptide. The effector:target ratio
was 20:1.
d Antigens were treated for 1 hr at 607 with 1% SDS and 2% mercaptoethanol as previously described (Schirmbeck et al., 1995a).
immunodominant domain in oligomeric gp120 (Roben et induce—possibly as a consequence of improper fold-
ing—a humoral response that was characterized by lowal., 1994, Sattentau and Moore, 1995; Fouts et al., 1997).
These observations are in agreement with our findings neutralizing activity although the titers of ELISA reactive
antibodies were relatively high (Lu et al., 1995). There-from chemical crosslinking experiments, indicating that
gp160 as well as the Env-TM derivatives is presented on fore, in contrast to the truncated derivatives (gp120-5TM,
gp120-20TM), incorporation of the complete HIV-1 exte-the VLPs in form of oligomeric (tetrameric) structures
(Deml et al., 1997). rior Env protein gp120 into Pr55gag VLPs (VLPgp120-TM)
by a heterologous transmembrane moiety resulted in theThe immunization of rabbits with Pr55gag/Env chimeric
particles also elicited antibodies that neutralized the in- stimulation of substantial titers of neutralizing antibodies,
even in the absence of the autologous gp41 transmem-fectivity of the homologous virus in MT4 cells. Sera taken
from animals immunized with VLPgp160 revealed a virus brane protein. Simultaneously, potential adverse side ef-
fects, suggested to be associated with parts of gp41neutralizing activity (90%) at dilutions of up to 1:128,
which was comparable to that reported in a previous (Ruegg et al., 1989; Ruegg and Strand, 1991; Yamada et
al., 1991), can be avoided.study using VLPgp160 pseudovirions purified from a vac-
cinia virus-driven expression system as immunogens Another novel aspect is that these lipoprotein particles
can be used as a carrier component for the delivery of(Haffar et al., 1991). However, identical neutralizing activi-
ties were also monitored in antisera obtained from rab- surface-fixed complex proteins to the MHC-I processing
and presentation pathway. A low dose of Pr55gag/Envbits after repeated administration of VLPs presenting the
complete gp120 exterior domain on their surface particles injected into BALB/c mice without adjuvants
efficiently primed HIV Env-specific CD8/ CTLs. This re-(VLPgp120-TM). In both cases, the titers of neutralizing
antibodies correlated rather with the titers of gp120-spe- sponse was detectable after a single ip, sc, or iv injection
of 1 mg carrier-fixed Env proteins. Particle-entrapped chi-cific than with the titers of V3-loop-specific antibodies.
By contrast antisera raised in animals after immunization meric gp120-TM derivatives and full-length gp160 were
equally effective in priming of CD8/ CTLs, when thewith VLPs presenting gp120 derivatives that were trun-
cated from the carboxy-terminus by 5 and 20 residues doses of the immunogen were adjusted to the amount
of particle-entrapped Env polypeptides (Fig. 3). However,(gp120-5TM, gp120-20TM) exhibited only weak neutraliz-
ing activity. This is in agreement with observations by in the case of identical doses of administered VLP pro-
tein, particles presenting the chimeric gp120-TM deriva-others, demonstrating that truncated Env glycoproteins
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tives were, obviously, due to an enhanced incorporation aluminum hydroxide or mineral oil significantly reduced
or abrogated the induction of a specific CD8/ CTL re-of the Env polypeptides (Fig. 1C), more efficient in induc-
ing a V3-specific CTL response than was the VLPgp160 sponse (Wagner et al., 1996). In contrast, no aluminum
hydroxide-induced down-regulation of CTL priming was(Table 3). The CTL response was not inducible by injec-
tion of equimolar or even 20 times higher doses of V3- observed following an immunization with Pr55gag/Env
particles. These observations also reflect conflicting re-loop-derived peptides or rgp120.
The mechanisms underlying the in vivo priming of V3- ports by others, demonstrating a suppressive or enhanc-
ing effect of adjuvants on the induction of cytotoxic T-specific CD8/ CTL by hybrid Pr55gag/Env VLPs are, how-
ever, still unclear at present. A trivial explanation for the cells, depending on the type of immunogen. Inefficient
or absent CTL priming to antigen in alum or mineral oilin vivo priming of V3-specific CD8/ CTL would be that a
limited degradation of surface-exposed gp120 during the has also been observed for Ty VLPs (Layton et al., 1993)
and HBsAg particles (Schirmbeck et al., 1994), whereaspurification procedure or following immunization by ex-
tracellular proteases generates peptides that allow MHC poliovirus VP1 or Sendai virus-derived immunogenic pep-
tides emulsified in complete Freund’s adjuvants stimu-class I-restricted presentation of the antigenic V3 peptide
from an antigen-presenting cell (APC). In this case, one lated class I-restricted CD8/ CTL response (Kast et al.,
1993; Kutubuddin et al., 1992). An explanation would bewould expect to observe CTL priming by injecting equi-
molar amounts of the immunogenic peptide or rgp120. that Pr55gag/V3 VLPs, carrying a small V3 loop epitope
within the particle, and hybrid Pr55gag/Env VLPs, present-This was not observed in many independent experi-
ments, even when a100-fold higher dose of the rgp120 ing the almost native gp120 or the complete wild-type
gp160 on the surface of the particle, enter the APC byor of a synthetic 18-mer V3 peptide was used.
Pr55gag VLPs are lipoprotein spheres, and conjugation different portals. Additionally, different subsets of APC
might be selected for the uptake and processing of theseof proteins with lipids or liposomes has been previously
demonstrated to facilitate their access to the endoge- divergent types of VLPs.
In summary, this study demonstrates that HIV-1nous processing pathway (Lopes and Chain, 1992; Mar-
tinon et al., 1992; Schild et al., 1991). The lipid compo- Pr55gag/Env chimeric VLPs administered in absence of
any adjuvant are good immunogens with respect to bothnents may therefore be supportive for the efficient uptake
and/or entry of these antigens to the MHC class I pro- the induction of neutralizing antibodies and an HIV-spe-
cific CTL response against multiple epitopes. These re-cessing pathway. However, particulate protein antigens,
such as SDS or heat-denatured proteins (Bevan, 1987; sults are in agreement with a similar strategy demonstra-
ting that DNA immunization with Gag- and Env-express-Schirmbeck et al., 1995a; Martinez-Kinader et al., 1995),
as well as Ty virus-like particles (Layton et al., 1993), ing plasmids was also capable of stimulating both arms
of the immune response (Lu et al., 1995). Ongoing experi-have also been demonstrated to be sufficient for the
induction of CD8/ CTLs. Thus, multimeric epitope pre- ments using VLPgp120-TM preparations for immunoge-
nicity studies in rhesus monkeys confirmed the inductionsentation may also contribute to the efficiency of CTL
priming by VLPs. of neutralizing antibodies and a CTL response to multiple
epitopes in a primate model (manuscript in preparation)A VLP/gp160 consists of about 1500 Pr55gag precursor
molecules and more than 200 copies of the Env protein and thus recommend further evaluation of recombinant,
chimeric VLPs as a potential HIV-1 candidate vaccine.as estimated by comparative immunoblotting of purified
Pr55gag/Env VLP’s with HIV virions. Therefore a single
uptake event introduces more than 200 copies of a CTL ACKNOWLEDGMENTS
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